Heads up: some links below are affiliate links — assume any provider we list may compensate us, at no cost to you. It never buys a better score, but the providers we work with are listed first. See our affiliate disclosure.
Alternatives · ranked for speed
Tru2u lands at #308 on our ranking with a Rx-Readiness Score of 30/100. If it isn't the right fit, here are the strongest alternatives on our shortlist — scored on the same readiness rubric of speed to first dose, flat pricing, no-video signup, access, molecule choice and a clean off-ramp.
Top alternative
A flat $239/mo semaglutide, $399/mo tirzepatide, no-video intake with free overnight shipping — but it's only live in 23 states, and most big population centers aren't on the list.
Ranked #108 · Grade C
A sublingual (under-the-tongue), not injectable, GLP-1 program — $189/mo semaglutide and $319/mo tirzepatide on a 6-month prepay plan, $209/mo and $359/mo on a shorter 2-month plan — serving 34 states plus DC.
Ranked #131 · Grade C
The sum is transparent and it is the seller's own: $99 a month for the service, plus the manufacturer's charge — $299 for the Zepbound starter pen, $149 for the Wegovy pill — giving $398 and $248. The first month is $25 instead of $99. Both of those manufacturer figures are LillyDirect's and NovoCare's own, so the arithmetic can be checked from outside, and it holds. What is not published is the ladder as your dose climbs.
Ranked #104 · Grade C
A one-product shop — compounded tirzepatide microdosing only, $89 the first month then $199/mo all-in, no live video visit described anywhere in the flow, and unusually candid on-site that the trial evidence for microdosing specifically is thin — but there's no semaglutide option at all, and no individual physician, pharmacy, or state list named anywhere on the site checked.
Ranked #140 · Grade C
Names four specific 503A compounding pharmacy partners directly — from $150/mo semaglutide, $241/mo tirzepatide on a 6-month plan, available as injection, drops, or pills — though state coverage isn't published.
Ranked #135 · Grade C
The lowest medication price on this roster, and a headline that still leaves out a required charge. Compounded semaglutide is $59 a month and tirzepatide $69, flat at every dose and cancellable at any time — both requiring a $199 annual membership the pricing line never mentions. Counted properly the first year is $907 for semaglutide, about $76 a month, and $1,027 for tirzepatide, about $86, which remains among the cheapest anywhere even after the fee. It is operated by Health For Everyone Inc., trading as CollectiveOS, and positioned on being brought to you by the founder of Thrive Market and on GLP-1s without the 500% markup. There is a 21-day free trial before the membership charge, after which the fee is non-refundable with no partial periods returned. The compounding pharmacies are never named, no state list is published, and no time to first dose is given.
Ranked #67 · Grade C
A no-membership-fee, quarterly-billed program — $167/mo semaglutide, $267/mo tirzepatide — bundling a GLP-1 fitness app, meal plans, and 1-on-1 nutrition coaching that most compounded-only competitors don't offer. It also publishes its own named comparison against Ro, Mochi Health, TrimRx, and Hims, an unusually direct move for this category.
Ranked #144 · Grade C
A small, physician-led practice — Dr. Tran Le personally, capped at ~500 patients — $199/mo semaglutide, $249/mo tirzepatide, all-inclusive, but limited to Texas and Utah only.
Ranked #88 · Grade C
A 3-month starter-bundle model — $99/mo semaglutide, $133/mo tirzepatide, medication plus shipping, consult and an injection kit included — serving all 50 states with no membership fees.
Ranked #111 · Grade C
A flat-fee solo-provider program — $249/mo semaglutide, $379/mo tirzepatide, Quest labs included, with an explicit 'no increases as you continue' promise — but coverage is limited to 20 named states.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Rx-Readiness Score. Scores are our editorial judgment per the methodology. Not medical advice; see our disclosure.